(Q51355945)

4 April 2018

title

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes (English)

1 reference

4 April 2018

0 references

0 references

1 reference

Wenying Yang

1

1 reference

4 April 2018

Yanfen Guan

2

1 reference

4 April 2018

Yue Shentu

3

1 reference

4 April 2018

Zhi Li

4

1 reference

4 April 2018

Amy O Johnson-Levonas

5

1 reference

4 April 2018

Samuel S Engel

6

1 reference

4 April 2018

Keith D Kaufman

7

1 reference

4 April 2018

Barry J Goldstein

8

1 reference

4 April 2018

Maria Alba

9

1 reference

4 April 2018

publication date

1 September 2012

1 reference

4 April 2018

published in

Journal of diabetes

1 reference

4 April 2018

volume

4

1 reference

4 April 2018

issue

3

1 reference

4 April 2018

page(s)

227-237

1 reference

4 April 2018

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Epidemic obesity and type 2 diabetes in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

The status of diabetes control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Comparative analysis of two rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Weight gain in type 2 diabetics with different treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00213.X

10.1111/J.1753-0407.2012.00213.X

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018